CliffBio
biologic

VIMKUNYA

Chikungunya Vaccine, Recombinant

Loss of exclusivityFebruary 2037FDA regulatory exclusivity expiry
CompanyBavarian Nordic A/S

Drug detail

Brand nameVIMKUNYA
Active ingredientChikungunya Vaccine, Recombinant
Strength40UG/0.8ML
Dosage formInjection
RouteIntramuscular
ModalityBiologic
FDA approvalFebruary 2025
Marketing statusRx

More from Bavarian Nordic A/S

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.

VIMKUNYA patent cliff — loss of exclusivity February 2037 | CliffBio